Benzinga | Aug 13, 2020 08:19AM EDT

SCYNEXIS Highlights Presentations On Ibrexafungerp's Potential For Treatment Of Vulvovaginal Candidiasis At Infectious Diseases Society for Obstetrics and Gynecology Meeting

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of two oral abstracts and a sponsored symposium at this year's Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Virtual Annual Meeting. IDSOG brings together some of the most prominent scientists and clinicians focused on infectious diseases for women, annually. The presentations will highlight clinical results from the Company's VANISH-303 Phase 3 trial, underscoring the potential of ibrexafungerp as a treatment for vaginal yeast infections, which affect millions of women in the U.S. every year, and include a discussion on the current antifungal diagnostic and treatment landscape.

"We are very excited to share our VANISH-303 data for the first time with the scientific community. The data demonstrated in a large clinical study, that ibrexafungerp was significantly superior when compared to placebo on multiple clinical and microbiological endpoints," said Dr. Nkechi Azie, Vice President of Clinical Development and Medical Affairs. "For a condition that affects many women but has limited treatment options, all within only one drug class, the market clearly needs a therapeutic alternative. This data, along with the VANISH-306 results, are part of a planned submission of a New Drug Application in the fourth quarter of this year."

Presentation details:

In vitro activity of ibrexafungerp in pH 7.0 and pH 4.5 testingTitle: environments against 187 fluconazole?susceptible and ?resistant candida species from vulvovaginal candidiasis patients.Presenter: Jack Sobel, MD, Wayne State UniversityType: Oral abstractDate: August 14, 2020Time: 2:55 p.m. EDT to 3:00 p.m. EDT Dr. Sobel will present data from an in vitro study performed in his laboratory at Wayne State University, demonstrating that acidic pHSummary: environments, like the vagina, do not adversely affect the activity and potency of ibrexafungerp unlike fluconazole, which is adversely affected when tested, in the same laboratory, in an in vitro acidic environment. Oral ibrexafungerp efficacy and safety in the treatment ofTitle: vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH?303)Presenter: Jane Schwebke, MD, University of Alabama at BirminghamType: Oral abstractDate: August 14, 2020Time: 3:00 p.m. EDT to 3:05 p.m. EDT Dr. Schwebke, an expert in the field of vaginitis and an ibrexafungerp investigator, will present data from the ibrexafungerpSummary: VANISH-303 study highlighting statistically significant superiority in multiple clinical and microbiological endpoints of ibrexafungerp versus placebo and a well-tolerated adverse event profile. Title: Current Challenges and Advancements in the Treatment of Vulvovaginal CandidiasisPresenter: Jack Sobel, MD, Wayne State UniversityType: Sponsored SymposiumDate: August 15, 2020Time: 11:00 a.m. EDT to 11:45 a.m. EDT Dr. Sobel, a world-renowned expert in the field of vaginitis withSummary: over 100 publications in vaginal diseases will provide an update of recent advances in the pathogenesis, diagnosis, and treatment of VVC.

Register to attend IDSOG Virtual Annual Meeting via link.

All presentations will be available on the SCYNEXIS website in the near future via link.